These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12700945)

  • 1. Immunocytokines: amplification of anti-cancer immunity.
    Davis CB; Gillies SD
    Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
    Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
    Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
    Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
    Front Immunol; 2020; 11():832. PubMed ID: 32457754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine/Antibody Fusion Protein Design and Evaluation.
    Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
    Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
    Ren Z; Zhang X; Fu YX
    Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytokines for cancer treatment: past, present and future.
    Neri D; Sondel PM
    Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.
    Ziffels B; Pretto F; Neri D
    Immunotherapy; 2018 Mar; 10(3):177-188. PubMed ID: 29370721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted cytokines for cancer immunotherapy.
    Lode HN; Reisfeld RA
    Immunol Res; 2000; 21(2-3):279-88. PubMed ID: 10852128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.
    Ongaro T; Guarino SR; Scietti L; Palamini M; Wulhfard S; Neri D; Villa A; Forneris F
    J Struct Biol; 2021 Mar; 213(1):107696. PubMed ID: 33493635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.